Drug intelligence / Profile preview

VG2062

Development stage: Phase 1
Lead developer: Virogin Biotech
Modality: Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
Administration: Intratumoral

Overview

VG2062 is an investigational oncolytic immunotherapy developed by Shanghai Virogin Biotech. It consists of a recombinant herpes simplex virus type 1 (HSV-1) engineered to express two potent immunostimulatory cytokines: human interleukin-12 (IL-12) and interleukin-15 (IL-15). The virus is designed to selectively replicate within and destroy tumor cells (oncolysis) while the localized expression of IL-12 and IL-15 promotes the activation and proliferation of T cells and natural killer (NK) cells, thereby enhancing the systemic anti-tumor immune response. The "dual-regulated" feature refers to the control of viral replication and transgene expression to optimize safety and efficacy. It is currently being evaluated in Phase I clinical trials for patients with advanced malignant solid tumors who are HSV-seropositive.

Other names: Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on VG2062.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VG2062.

Explore the full profile